Quiz: What Agent Does ASCO Recommend for Frontline Stage IV Lung Cancer Treatment?

Quiz: What Agent Does ASCO Recommend for Frontline Stage IV Lung Cancer Treatment?

September 1, 2017

What single agent does the new ASCO guideline recommend for first-line treatment of patients with stage IV non-small-cell lung cancer without positive markers but with high PD-L1 expression? Is there an age limit for use of SBRT for early-stage lung cancer? Test your knowledge in our latest quiz.

Is there an age limit for use of stereotactic body radiation therapy (SBRT) for early-stage lung cancer? What single agent does the new American Society of Clinical Oncology (ASCO) guideline recommend for first-line treatment of patients with stage IV non-small-cell lung cancer (NSCLC) without positive markers but with high programmed death ligand 1 (PD-L1) expression? Test your knowledge in our latest quiz.

Question 1

Answer and Question 2 on Next Page »

Answer

D.Pembrolizumab

According to the ASCO guideline, if a patient has low PD-L1 expression, standard chemotherapy should be offered. For second-line treatment, single-agent atezolizumab, nivolumab, or pembrolizumab may be used if the first-line regimen did not contain immune checkpoint therapy. Crizotinib is recommended for patients with ROS1 gene rearrangement who received no prior crizotinib therapy.

Question 2

Answer and Question 3 on Next Page »

Answer

A. 3%

According to the report, the median age of the patients was 62 years; the majority (71%) were never smokers and presented with advanced disease at diagnosis. Median survival for the 12 patients who received HER2-targeted therapies was 2.1 years vs 1.4 years for the 12 patients who did not (P = .48). The authors noted that “HER2-directed therapies should be investigated in this subgroup of patients.”

Question 3

Answer and Question 4 on Next Page »

Answer

D. Recent smokers

Recent smokers had a hazard ratio (HR) of 0.38 (P P P = .0208 and HR, 1.62; P = .236) and never smokers (HR, 1.025; P = .971 and HR, 1.33; P = .638), respectively. “Sequencing data revealed that mutational burden was not associated with veliparib benefit,” the study concluded.

Question 4

Answer and Question 5 on Next Page »

Answer

A. Median overall survival was similar between both arms

The study authors concluded, “The addition of palifosfamide to carboplatin and etoposide failed to improve survival in early-stage SCLC.” Serious adverse events did not differ significantly between the two arms.

Question 5

Answer on Next Page »

Answer

A. Higher rate of grade 3 or higher pneumonitis

The grade 3 or higher pneumonitis rate was 1.3% vs 1.6% vs 1.5% (P = 1.0) in patients aged